News & Updates

Treatment with canakinumab appears beneficial to patients with advanced nonsmall cell lung cancer (NSCLC) with low T-cell infiltration (ie, low total count or immune desert phenotype), results of predefined exploratory biomarker analyses from the CANOPY-1 have shown.

For patients with HER2-positive early breast cancer (BC), 1 year of adjuvant trastuzumab remains standard of care (SoC) as noninferiority is not demonstrated for a shortened 9-week course of treatment in the final analysis of the phase III ShortHER trial. However, long-term data from the trial provide reassurance in case early discontinuation is needed in low-risk patients.

Patients with previously untreated, locally advanced, or metastatic squamous non-small-cell lung cancer (NSCLC) may derive benefit from the addition of the novel anti-PD-1 monoclonal antibody serplulimab to chemotherapy, according to the final analysis of the phase III ASTRUM-004 study.

Trastuzumab deruxtecan (T-DXd) at both 5.4 mg/kg and 6.4 mg/kg doses provides clinically meaningful and durable responses in patients with previously treated HER2-mutant (HER2m) metastatic non-small-cell lung cancer (mNSCLC), with the 5.4 mg/kg dose showing a more favourable benefit/risk profile, according to primary results of the phase II DESTINY-Lung02 trial.

Visceral fat area (VFA) is a reliable prognostic indicator of muscle mass and is associated with nutritional, immune, and inflammatory status in patients with diverse types of cancer, such as gastric, colorectal, and nonsmall-cell lung cancers (NSCLC), claims a recent study.

In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).

Pretreatment level of serum carcinoembryonic antigen (CEA) is independently associated with overall and disease-free survival among patients with nonsmall cell lung cancer (NSCLC), reports a study. The same marker is also used for the prognosis of patients with the same pathologic stages.